Drugs / ADG206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05614258 | Feb 2023 → Jun 2025 overdue | — | Adagene Inc | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADG206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05614258 ↗ |
| Action | Activate | “as a co-stimulatory receptor agonist” NCT05614258 ↗ |
| Route | Intravenous | “ADG206 will be administered by intravenous infusion” NCT05614258 ↗ |